数据显示，中国IBD负担在未来十年内将持续上升^[1]。尽管生物制剂等先进疗法的出现为IBD的治疗带来了革命性变化，但当前治疗仍存在显著局限^[2,3]：30%~50%的患者原发性无应答；50%的患者面临继发性失应答，更有80%的患者难以达到理想的深度缓解（临床缓解+内镜愈合）。看似“百花齐放”，其实“天花板”效应依然明显。

如何破局？如何满足患者的需求？随着古塞奇尤单抗相继在我国取得克罗恩病（CD）和溃疡性结肠炎（UC）的适应证，我们离解决这些问题又近了一步。在第十八届强生免疫消化学术论坛（JIS）上，中山大学附属第六医院高翔教授在主旨报告中，详细介绍了古塞奇尤单抗的独特机制与卓越疗效。报告的精华内容整理如下。

参考文献

1. Xu L, He B, Sun Y, et al. Incidence of Inflammatory Bowel Disease in Urban China: A Nationwide Population-based Study. Clin Gastroenterol Hepatol. 2023;21(13):3379-3386.e29.

2. Kayal M, et al. Clin Gastroenterol Hepatol. 2023 May;21(5):1348-1350.3  Kayal M, Ungaro RC, Bader G, Colombel JF, Sandborn WJ, Stalgis C. Net Remission Rates with Biologic Treatment in Crohn's Disease: A Reappraisal of the Clinical Trial Data. Clin Gastroenterol Hepatol. 2023;21(5):1348-1350. doi:10.1016/j.cgh.2022.02.044

3. Lusetti F, et al. lmmunotherapy. 2024;16(9):581-595.   Lusetti F, D'Amico F, Allocca M, et al. Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn's disease. Immunotherapy. 2024;16(9):581-595. doi:10.2217/imt-2023-0219

4. 强生宣布特诺雅达®特诺雅®获批成为中国首个治疗活动性克罗恩病的白介素23抑制剂.
https://www.xian-janssen.com.cn/news/5155

5. 强生宣布特诺雅达®特诺雅®在华获批成为首个治疗溃疡性结肠炎的白介素23抑制剂.
https://www.xian-janssen.com.cn/news/5257

6. Bourgonje AR,  et al. Targeting the Interleukin 23 Pathway in Inflammatory Bowel Disease. Gastroenterology. 2025 Jan;168(1):29-52.

7. Teng M, et al. Nat Med. 2015;21(7):719-729.Teng MW, Bowman EP, McElwee JJ, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21(7):719-729.

8. 宋禹霏, 冯茹. 中性粒细胞CD64在血液肿瘤患者病原微生物感染诊断中的应用现状. 国际输血及血液学杂志, 2021, 44(6) :  461-466.

9. Chapuy L, Bsat M, Sarkizova S, et al. Two distinct colonic CD14+ subsets characterized by single-cell RNA profiling in Crohn's disease [published correction appears in Mucosal Immunol. 2020 Mar;13(2):381.]. Mucosal Immunol. 2019;12(3):703-719.

10. Chapuy L, Bsat M, Rubio M, et al. IL-12 and Mucosal CD14+ Monocyte-Like Cells Induce IL-8 in Colonic Memory CD4+ T Cells of Patients With Ulcerative Colitis but not Crohn's Disease. J Crohns Colitis. 2020;14(1):79-95.

11. Kamada N, Hisamatsu T, Okamoto S, et al. Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J Clin Invest. 2008;118(6):2269-2280.

12. Atreya et al. Guselkumab, an IL-23p19 subunit-specific monoclonal antibody, binds CD64+ myeloid cells and potently neutralises IL-23 produced from the same cells. ECCO 2023. Poster P504.

13. Krueger J, Eyerich K , Bissonnette R ,et al. ISID 2023. Poster 1591.

14. Zhou L, Wang Y, Wan Q, et al. A non-clinical comparative study of IL-23 antibodies in psoriasis. MAbs. 2021;13(1):1964420.

15. Richards D, Venkat S, Ruane D, et al. Guselkumab Decreases Key Cellular Inflammatory Processes Across Ileum and Colon Tissue in Crohn’s Disease. P0950 ACG 2024

16. Sridhar et al. Guselkumab induction restores intestinal immune homeostasis and promotes epithelial repair in moderately to severely active Ulcerative Colitis. ECCO 2024. OP23.

17. Sandborn WJ, D'Haens GR, Reinisch W, et al. Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study [published correction appears in Gastroenterology. 2023 Dec;165(6):1588.]. Gastroenterology. 2022;162(6):1650-1664.e8.

18. https://www.jnj.com/media-center/press-releases/tremfya-guselkumab-demonstrates-superiority-versus-stelara-ustekinumab-in-phase-3-crohns-disease-program

19. Nakase H, Chen B, Cao Q, et al Guselkumab efficacy and safety in East Asian participants with moderate to severely active Crohn’s disease: Subgroup analysis of the GALAXI 2 & 3 Phase 3 studies. ECCO 2025. P0976

20. Afzali A, Danese S, Panaccione R, et al. Efficacy and safety of guselkumab for Crohn’s disease through 3 years: GALAXI-1 long-term extension. UEGW2023. OP020.

21. Pouillon L, Travis S, Bossuyt P, Danese S, Peyrin-Biroulet L. Head-to-head trials in inflammatory bowel disease: past, present and future [published correction appears in Nat Rev Gastroenterol Hepatol. 2021 Feb;18(2):143.]. Nat Rev Gastroenterol Hepatol. 2020;17(6):365-376.

22. Panaccione, R et al. Efficacy and safety of guselkumab therapy in patients with moderately to severely active Crohn’s disease: results of the GALAXI 2 & 3 phase 3 studies. DDW2024. Oral presentation (Abstract #1057b)

23. Vuyyuru SK, et al. Efficacy and Safety of IL-12/23 and IL-23 Inhibitors for Crohn's Disease: Systematic Review and Meta-Analysis. Dig Dis Sci. 2023 Sep;68(9):3702-3713.

24. Researcher View | A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | ClinicalTrials.gov

25. Study Details | Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | ClinicalTrials.gov

26. Peyrin-Biroulet L, Allegretti JR, Rubin DT, et al. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study. Gastroenterology. 2023;165(6):1443-1457. doi:10.1053/j.gastro.2023.08.038

27. Rubin DT, et al. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. Lancet. 2025 Jan 4;405(10472):33-49. 

28. Lichtenstein GR, et al. Efficacy and safety of guselkumab for ulcerative colitis through week 92 of the QUASAR long-term extension study. DDW2025. Poster #4241842

29. Chen B, Cao Q, Wang Y et al. The efficacy and safety of guselkumab induction therapy in Chinese patients with moderately to severely active ulcerative colitis. AOCC 2024. OP025

30. Shehab M, et al. Comparative Efficacy of Biologics and Small Molecule Therapies in Improving Patient-Reported Outcomes in Ulcerative Colitis: Systematic Review and Network Meta-Analysis. Inflamm Bowel Dis. 2024 Aug 13:izae163.

31. Estevinho MM, et al. Network Meta-Analysis: Histologic and Histo-Endoscopic Improvement and Remission With Advanced Therapy in Ulcerative Colitis. Aliment Pharmacol Ther. 2024 Nov;60(10):1276-1292.

32. Sands BE, Panaccione R, Danese,S et al. Safety of guselkumab in Inflammatory Bowel Disease up to 1 year: Integrated safety analysis of phase 2 and 3 studies in Crohn’s Disease and Ulcerative Colitis. ECCO 2025 P0608